OKYO Pharma Announces Chief Development Officer Acquires Shares Amid Plans for Phase 2b/3 NCP Study

OKYO Pharma's Chief Development Officer and Director, Gary Jacob, acquired 30,980 shares of the company's ordinary shares on NASDAQ at $1.59. Jacob's total holding now stands at 108,920 shares. OKYO is developing investigational therapies for neuropathic corneal pain and inflammatory eye diseases, with its flagship drug urcosimod currently in Phase 2 trials.